Las Vegas, NV -- (SBWIRE) -- 12/30/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more. EquityObserver.com issues a special report on the following stocks:Synthetic Biologics Inc(NYSEMKT:SYN),Novacopper Inc(NYSEMKT:NCQ),Zhone Technologies Inc(NASDAQ:ZHNE),StemCells Inc(NASDAQ:STEM)
Synthetic Biologics Inc(NYSEMKT:SYN)managed to keep its loss at -0.64% on above-normal volume of 991,756.00shares. The stock settled at $1.55, after floating in a range of $1.53 - 1.70. Its latest price has reached market capitalization of $69.21M. Its 52-week range has been $0.95 - 2.10. Synthetic Biologics, Inc., formerly Adeona Pharmaceuticals, Inc., is a biotechnology company focused on the development of synthetic deoxyribonucleic acid (DNA)-based therapeutics and disease-modifying medicines for serious illnesses.
How Should Investors Trade SYN Now?Don’t Miss out a Special Trend Analysis
Novacopper Inc(NYSEMKT:NCQ)trading on a volume of 988,603.00shares, higher than its standard daily volume. Shares have been closed at $1.57.Over the last twelve months, the stock has lost-13.74% and faced a worst price of $1.36.NovaCopper Inc. (NovaCopper) is a base metals exploration company.
Is NCQ a Solid Investment at These Levels?Read This Report for Details
Zhone Technologies Inc(NASDAQ:ZHNE)is up at $5.28 on above- normal volume of 967,129.00shares during the last trading day. The stock has its 12-month range $0.42 - 6.40. Its Intraday range is $5.17 - 5.58.Zhone Technologies Inc. (Zhone) designs, develops and manufactures communications networks equipment for telecommunications.
How Should Investors Trade ZHNE Now?Don’t Miss out a Special Trend Analysis
In the last trading day, StemCells Inc(NASDAQ:STEM)is on high volume, trading at a volume of versus its average daily volume ratio 965,052.00/476,534.00 shares. At $1.28, the stock has attained market capitalization of 70.36M.StemCells, Inc. (StemCells) is engaged in the research, development, and commercialization of stem cell therapeutics and related tools and technologies for academia and industry.
Will Investors Buy STEM After Reading This News?Just Go Here and Find Out
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/disclaimer-2/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)